Do HMG-CoA reductase inhibitors improve kidney function? The saga continues

被引：9

作者：

Campese, Vito M. ^{[1
]}

Ku, Elaine ^{[1
]}

Bigazzi, Roberto ^{[1
]}

Bianchi, Stefano ^{[1
]}

机构：

[1] Univ So Calif, Keck Sch Med, Div Nephrol, Los Angeles, CA 90033 USA

来源：

JOURNAL OF NEPHROLOGY | 2011年 / 24卷 / 05期

关键词：

Chronic kidney disease; Proteinuria; Statins; C-REACTIVE PROTEIN; CORONARY-HEART-DISEASE; RENAL-FUNCTION; ROSUVASTATIN; ATORVASTATIN; PROGRESSION; DYSLIPIDEMIA; EFFICACY; STATINS; WOMEN;

D O I：

10.5301/jn.5000024

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Several reviews have addressed the role of dyslipidemia in renal injury and the potential renal protective effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins). Experimental evidence in animals strongly supports the concept that statins may be renal protective. However, data in humans are scanty and contradictory. A recent controlled study using rosuvastatin has cast some doubts on the renal protective effect of this drug. This article reviews the available evidence pro and con the renal protective effects of statins in human subjects.

引用

页码：550 / 553

页数：4

共 50 条

[11] Pleiotropic effects of the HMG-CoA reductase inhibitors
Mihos, Christos G.
Santana, Orlando
INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2011, 4 : 261 - 271
[12] Association of HMG-CoA reductase inhibitors with neuropathy
Backes, JM
Howard, PA
ANNALS OF PHARMACOTHERAPY, 2003, 37 (02) : 274 - 278
[13] HMG-CoA REDUCTASE INHIBITORS, ANGIOGENESIS AND CANCER
Martinez Gonzalez, J.
Badimon, L.
CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2005, 17 : 31 - 39
[14] HMG-CoA reductase inhibitors for the prevention of nephropathy
Maisch, NM
Pezzillo, KK
ANNALS OF PHARMACOTHERAPY, 2004, 38 (02) : 342 - 345
[15] HMG-CoA Reductase Inhibitors and Myotoxicity
Memduh Ucar
Tom Mjörndal
Rune Dahlqvist
Drug Safety, 2000, 22 : 441 - 457
[16] Renal hemodynamic effects of the HMG-CoA reductase inhibitors in autosomal dominant polycystic kidney disease
Zand, Ladan
Torres, Vicente E.
Larson, Timothy S.
King, Bernard F.
Sethi, Sanjeev
Bergstralh, Eric J.
Angioi, Andrea
Fervenza, Fernando C.
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 (08) : 1290 - 1295
[17] Direct vascular effects of HMG-CoA reductase inhibitors
Bellosta, S
Bernini, F
Ferri, N
Quarato, P
Canavesi, M
Arnaboldi, L
Fumagalli, R
Paoletti, R
Corsini, A
ATHEROSCLEROSIS, 1998, 137 : S101 - S109
[18] Aspects of Antithrombotic Effect of HMG-CoA Reductase Inhibitors
贺石林
血栓与止血学, 2005, (01) : 3 - 4
[19] HMG-CoA reductase inhibitors: Is the endothelium the main target
Puddu, P
Puddu, GM
Muscari, A
CARDIOLOGY, 2001, 95 (01) : 9 - 13
[20] HMG-CoA Reductase Inhibitors for Traumatic Brain Injury
Kalman Katlowitz
Shankar Gopinath
Jovany Cruz Navarro
Claudia Robertson
Neurotherapeutics, 2023, 20 : 1538 - 1545

← 1 2 3 4 5 →